Medtronic

Medtronic has announced CE mark approval for two new CRT devices which automatically adapt to patients’ electrical rhythms, improving response to life-saving therapy.

A first patient has been successfully implanted with Medtronic’s DBS device as Functional Neuromodulation Ltd initiates the ADvance Study in the U.S. and Canada to assess the therapy in patients with mild Alzheimer’s disease.

Medtronic, Inc. has announced the FDA 510(k) clearance for its Aquamantys®3 BSC 9.1S Bipolar Sealer with Cutting, a new addition to the orthopaedic portfolio of the company’s Advanced Energy business. Combining sealing with cutting in a single device should make procedures more efficient, according to the company.

NeuroLogica has announced the integration of NeuroLogica’s portable BodyTom™ 32-slice CT scanner with Medtronic’s StealthStation® S7® surgical navigation system.

The life of a medtech company is never straightforward is it? Just as Medtronic is celebrating victory in a stent graft patent case involving W.L.Gore it also emerges that it is being sued for historical royalty payments of at least $7M, which a University claims it is due because of confusing accounting practices.

US Regulatory Agency, the FDA has selected Medtronic’s thoracic stent graft development product for inclusion in its early feasibility pilot program.

With effect from 1st June 2012, Tissuemed Ltd. and Medtronic Inc. have agreed that the medtech giant’s distribution of Tissuemed’s dural sealant film will revert back to Tissuemed. In a statement on its website Tissuemed states this is a commercial decision to enable it to actively control commercialisation of its core sealant product.

Medtronic, Inc. has synchronised the U.S. launch of the recently FDA cleared Endurant® II AAA Stent Graft System with the Society for Vascular Surgery’s Vascular Annual Meeting being held right now. The company claims its new iteration enhances access and ease of use compared with the first generation product.

According to study results presented at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress in Philadelphia, Medtronic’s Resolute® drug-eluting stent (DES) from Medtronic, Inc. yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow-up.

In the same week that the device giant Medtronic announced better than expected financial results including headline items like a 28% year-on- year quarterly earnings increase, it has also been revealed that the company is to shed around 1000 jobs.

It’s a solid set of figures with some genuine highlights, not least the OUS sales increase and positive results from some key new product introductions and acquisitions. Medtronic is sounding pretty upbeat and putting a few bad experiences behind it.

Californian company Vessix Vascular Inc has announced the CE marking of its rather clever RF balloon for renal denervation. The company claims its approach means faster treatment than the other systems on the market and its clinical performance will shortly be presented at the EuroPCR Conference in Paris May 15-18.

More positive signs for Medtronic’s Renal Denervation System as clinical trial results suggest sustained and significant blood pressure reduction.

Medtronic’s clinical ambitions are laid bare at CX34 as it announces the imminent start of its 1500 patient evaluation of peripheral artery treatment using its IN.PACT Drug-eluting balloon.

More from CX34 as Medtronic’s Endurant AAA Stent Graft 2 year data gets a positive airing.

Medtronic’s new electronic power instruments are aimed at reducing surgeon fatigue and enhancing control in complex spinal reconstructions.